Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Часто задаваемые вопросы
В каком секторе работает Apollomics Inc. Class A Ordinary Shares (APLM)?
Apollomics Inc. Class A Ordinary Shares относится к сектору Здравоохранение.
Какова текущая цена акций Apollomics Inc. Class A Ordinary Shares (APLM)?
По последним данным, цена акций Apollomics Inc. Class A Ordinary Shares составляет 23,40 $, предыдущее закрытие — 17,37 $. За последнюю торговую сессию акции Apollomics Inc. Class A Ordinary Shares выросли на 6,03 $, что соответствует росту на 34,72%.
Выплачивает ли Apollomics Inc. Class A Ordinary Shares (APLM) дивиденды?
Нет, Apollomics Inc. Class A Ordinary Shares не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Apollomics Inc. Class A Ordinary Shares (APLM)?
У компании Apollomics Inc. Class A Ordinary Shares бета 1.436, что указывает на повышенную волатильность по сравнению с рынком.
